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Plasmablastic lymphoma (PBL) is a rare and aggressive variant of diffuse large B cell lymphoma. The prognosis of
PBL patients is poor. The majority of patients succumb to a fulminant disease course, with most dying in the first
year after diagnosis. The small number of HIV-negative PBL cases reported in the literature to date is composed of
single case reports and small case series. Consequently, the natural history of the disease in HIV-negative individuals
and the optimum treatment are not well characterized. Intensive induction chemotherapy has been associated with
marked improved overall survival. However the optimal regimen has not been defined. We describe the third case
of PBL of the maxillary sinus which occurred in a 24-year old HIV-negative man. We outline the clinicopathological
features and report success using a hyper-CVAD regimen with 6 cycles and consolidation radiation therapy yielding
a complete remission of four years.
Keywords: Plasmablastic lymphoma, PBL, HIV-negative, Maxillary sinusIntroduction
Plasmablastic lymphoma (PBL) is a recently recognized
aggressive non-Hodgkin’s B-cell lymphoma which occurs
predominantly in HIV seropositive individuals and shows
a predilection for the oral cavity. Overall, PBL is associ-
ated with early dissemination, poor response to ther-
apy and limited survival. To date, treatment responses
are usually partial and temporary. Since the first de-
scription of PBL in 1997 (Delecluse et al. 1997), the
treatment of PBL in HIV-positive patients has been en-
hanced with the addition of highly active antiretroviral
therapy (ART) (Guan et al. 2011; Castillo et al. 2010).
However, a small retrospective analysis (Castillo et al.
2012) found that HIV-associated PBL has a poor overall
prognosis which is not impacted favorably by more inten-
sive chemotherapeutic regimens in the ART era.
We report an unusual case of plasmablastic lymphoma
(PBL) of the maxillary sinus in a young HIV-negative
man. To our knowledge this is the third reported case
(Nguyen et al. 2003; Colomo et al. 2004) of this entity* Correspondence: Christine.Saraceni@lvhn.org
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in any medium, provided the original work is poriginating in the maxillary sinus. There have been 79
previously reported cases of HIV-negative PBL, with a
majority of these cases arising in the post-transplant set-
ting or immunosuppressed state. Only a small subset of
reported cases have occurred in immunocompetent pa-
tients. (Delecluse et al. 1997; Nguyen et al. 2003; Colomo
et al. 2004; Scheper et al. 2005; Takahashi et al. 2009;
Thakral et al. 2009; Teruya-Feldstein et al. 2004; Kim
et al. 2009; Cha et al. 2010; Kravetz et al. 2006; Masgala
et al. 2007;Lin et al. 2004; Khurana & Jaipota 2010;
Pruneri et al. 1998; Lee et al. 2006; Gogia & Bakhshi
2010; Lipstein et al. 2010; Mihaljevic et al. 2011; Guan
et al. 2011; Brahmania et al. 2011; Mondal et al. 2011;
Mansoor et al. 2012) Table 1. A standardized, optimal
chemotherapeutic regime for PBL is yet undefined. To
date, initial therapy has included lymphoma-specific
multi-agent systemic chemotherapy with or without
consolidation radiation and hematopoietic stem cell
transplantation. The present case demonstrates a dur-
able clinical, pathologic and radiographic remission of
PBL following aggressive chemotherapy with the MD
Anderson hyper-CVAD regimen (Kantarjian et al. 2000),
and consolidation radiation therapy yielding a complete
remission of four years. This report highlights a feasiblean Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Reported plasmablastic lymphoma cases in HIV seronegative, immunocompetent patients with outcomes
Report Demographics Location EBV + Treatment regimen Prognosis
Delecluse et al. 1997 75 F Gingiva UNK RT (UNK) ↓ 3 mo *
Pruneri et al. 1998 53 F Gastric UNK PROMACE / cytaBOM x 6 cycles ↑19 mo
Nguyen et al. 2003 42 M Nasal cavity Sinuses (+) Hyper-CVAD → RT (40 Gy) ↑ 6 mo
Colomo et al. 2004 56 F Oral Mucosa (−) UNK UNK
86 F Maxillary Sinus (+) UNK ↓ 4 mo
82 M Lymph Node (+) UNK UNK
Lin et al. 2004 82 M Cervical LN (+) CHOP x 6 cycles UNK
Teruya-Feldstein et al. 2004 56 M Sigmoid colon (−) CODOX/M-IVAC ↓ 3 mo
23 M Neck mass, sinus UNK Hyper-CVAD, ↓12 mo
49 M Bone PBSCT ↓ 14 mo
61 M Liver, lung (−) CHOP x 6 cycles ↓ 12 mo
(+) CODOX/M-IVAC
Scheper et al. 2005 49 M Mandible (+) UNK UNK
Kravetz et al. 2006 66 M Upper Extremity (+) Hyper-CVAD ↑ 15 mo
Lee et al. 2006 66 M Gingival Mass (−) Chemotherapy → RT (UNK) ↓ 8 mo
Masgala et al. 2007 67 F Visceral cranium, cervix, thorax (−) Cisplatin, 5-FU, leukovorin x 6 cycles ↓ 23 mo
→ CHOP x 6 cycles
→ CHOP-bleomycin
→ RT (2000 Gy)
Kim et al. 2009 67 M Terminal ileum (−) Surgery ↓ 3 mo
66 M Oral cavity (−) Chemotherapy → ↓ 8 mo
8 M Tonsil (−) RT (UNK) ↑ 36 mo
72 F Paranasal sinus (+) Chemotherapy ↑ 6 mo
61 M Stomach (−) (UNK) ↓ 3 mo
13 M Meninges (−) Chemotherapy (UNK) Surgery ↓ 7 mo
Chemotherapy → RT (UNK)
Takahashi et al. 2009 76 M Retroperitoneum (+) Prednisolone ↓ 35 days
Thakral et al. 2009 84 F Psoas muscle (−) RT (UNK) ↓ 1 mo
Cha et al. 2010 60 M Jejunum (−) CHOP x 6 cycles ↑ 24 mo
→ ESHAP salvage
→ RT (UNK)
Gogia and Bakhshi 2010 2 F Jaw - Mandible UNK Chemotherapy (UNK) ↓ sepsis
→ RT (4 Gy)
Khurana and Jaipota 2010 55 M Cervical LN UNK CHOP UNK
Lipstein et al. 2010 68 M Cervical LN (−) R-CHOP, DICE, R-CBortP ↓ 1 mo
Mihaljevic et al. 2011 60 M Gastric (−) CHOP ↓ 1 mo
Guan et al. 2011 58 M Posterior teeth mucosa (−) Chemotherapy → XRT ↓ 1 mo
Brahmania et al. 2011 59 M Ano-rectal junction (−) CHOP x 3 cycles → XRT ↑ 5 years
Mondal et al. 2011 47 F Humerus UNK CHOP x 3 cycles ↑ 12 mo
Mansoor et al. 2012 77 F Cecal/Lung/LN (−) High dose steroids ↓ 3 weeks
Present Case 2012 24 M Maxillary Sinus (+) Hyper-CVAD → RT (45 Gy) ↑ 4 years
RT – radiotherapy, UNK – unknown, ↑ alive, ↓ died of disease, EBV – Epstein-Barr virus, HIV – Human Immunodeficiency Virus, M – male, F – female, y – years old,
LN – lymph nodes, * dead of unrelated causes, Gy – gray (unit), PBSCT – peripheral blood stem cell transplant.
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Figure 3 CD138, immunohistochemical stain demonstrates
plasmacytic differentiation.
Figure 1 CT image of the brain, axial view – There is a large
expansile soft tissue mass centered within the left maxillary
sinus with extensive osseous dehiscence. Tumor extends into the
left orbital floor, nasal cavity, left nasopharynx, left pterygopalatine
fossa, left premaxillary space, and left infratemporal fossa.
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contributes to the small but increasing body of reported
cases.
Case report
A 24- year old Hispanic man presented with symptoms
of chronic sinusitis for two months. He complained of
nasal congestion, left-sided facial asymmetry, pain in
the left cheek region as well as numbness around theFigure 2 H&E , (hematoxylin and eosin), large sheets of mostly
large plasmacytoid appearing mononuclear cells with
moderately dispersed nuclear chromatin and one to several
small nucleoli are present.left nostril and left side of the upper lip. Additional
constitutional complaints included low grade fever and
intermittent night sweats in the 1 – 2 months prior to
presentation. He underwent two courses of antibiotics with
minimal response. His medical history was unremarkable,
including no prior history of sexually transmitted diseases,
HIV infection or immunosuppressive conditions.
On physical examination, the patient’s face was
grossly asymmetric with left cheek swelling that crowded
the left eye. Extraocular muscles and pupillary responses
were intact bilaterally. Intraoral examination showed pro-
trusion of the mucosal aspect of the left cheek. The
mass was abutting the left nostril. A one centimeter
left submandibular lymph node was palpable.
Computed tomography (CT) scan of the head and
neck revealed a 5.3 x 5.0 cm left maxillary sinus mass,
involving the nasal septum and extending through the
medial maxillary sinus wall, into the left nasal canalFigure 4 Lambda, light chain immunohistological stain shows
positivity in neoplastic cells.
Figure 5 Ki-67, immunohistochemical stain shows a high
proliferative rate.
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and abutted the inferior rectus muscle. Biopsy of the
mass revealed a monotonous, highly proliferative sheet of
mononuclear cells (Figure 2). Neoplastic cells were
strongly positive for CD 138 (Figure 3), lambda light
chain (Figure 4) and Ki-67 [90% expression, Figure 5).
In situ hybridization revealed extensive positivity for
Epstein-Barr virus-encoded small RNA (EBER) [Leica,
Buffalo Grove, IL] (Figure 6). All other negative markers
included CD20, CD 56, LCA (CD45), CD3, CD10, kappa
light chain, BCL 1, BCL 2, BCL 6, and EBV Latent Mem-
brane Protein. Further staging workup included a bone
marrow biopsy and aspirate which did not show any
evidence of plasma cell dyscrasia or plasmablastic
lymphoma. PET/CT scan showed the 5.3 × 5 cm
hypermetabolic mass in the left maxillary sinus, a 14 × 6
mm cervical lymph node between the sternocleidomastoid
muscle and internal jugular vein and bilateral sub-Figure 6 EBER in situ hybridization shows, extensive positivity.centimeter level II lymph nodes (Figure 7). No other evi-
dence of metastatic disease was present. Since the mass
involved maxillary sinus, a diagnostic lumbar puncture
was also performed which was negative by cytology and
flow cytometry for involvement by the lymphoma. Labora-
tory studies showed normal chemistries, mildly elevated
serum lactate dehydrogenase at 217 IU/L [normal <190
IU/L] Beta-2 microglobulin was normal at 1.4 mg/L
[range 0.7 – 3.4 mg/L]. Serum and urine protein elec-
trophoresis and immunofixation showed no evidence of
monoclonal gammopathy. Enzyme-linked immunosorb-
ent assay /Western Blot for HIV 1 and 2 were negative.
Hepatitis A, B, and C serologies, polymerase chain reac-
tion for herpes simplex virus 1 and 2 and human herpes-
virus 8 were negative. The lymphoma was staged as IIE
and the IPI Score was 0.Figure 7 Whole Body PET/CT (a) Diagnostic Staging PET/CT –
There is a hypermetabolic mass centered in the left maxillary
sinus. The left cervical lymph nodes between the
sternocleomastoid muscle and internal jugular vein as well as
subcentimeter level 2 lymph nodes are also hypermetabolic.
Figure 8 Whole Body PET/CT (b) Post-treatment – There is no
significant FDG uptake seen within the left maxillary sinus,
consistent with complete metabolic response to therapy. There
are no pathologically enhancing cervical, axillary, mediastinal or hilar
lymph nodes or other sites of metabolically active tumor.
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hyper-CVAD involving high doses of cyclophosphamide,
vincristine, doxorubicin and prednisone (odd cycles x3),
alternating with high doses of methotrexate and cytosine
arabinoside (even cycles x 3). He received intrathecal
methotrexate and cytosine arabinoside with each of the six
cycles of chemotherapy and tolerated treatment well. Tox-
icities during treatment included febrile neutropenia with
coagulase negative staphylococcus ventriculitis requiring
Ommaya shunt removal and prolonged intravenous and
intrathecal vancomycin after cycle 2 as well as Herpes zos-
ter and Giardia lamblia infections after cycle 6. A repeat
biopsy from the maxillary sinus showed the patient to be
in complete pathologic remission confirming negative
radiographic findings (Figure 8). He also underwent
post-chemotherapy consolidation radiation by intensity-modulated radiation therapy (IMRT) for a total dose of 45
Gy. He patient is still alive and well 4 years after the initial
diagnosis with no evidence of recurrence.
Discussion
Plasmablastic lymphoma is a rare and rapidly progressive
variety of diffuse large B-cell lymphoma that was originally
reported exclusively in the jaw and oral mucosa of
male-predominant HIV-positive patients (Delecluse
et al. 1997; Colomo et al. 2004; Yotsumoto et al. 2009). Its
hallmarks include extensive local invasion, rapid dissemin-
ation and recalcitrance to treatment (Colomo et al. 2004;
Scheper et al. 2005; Valenzuela et al. 2008). PBL is over-
whelmingly associated with immunodeficiency states par-
ticularly precedent HIV infection. A substantial minority
of cases occur in HIV-negative patients following solid
organ transplantation or immunosuppressive therapy
(Colomo et al. 2004; Takahashi et al. 2009; Raviele et al.
2009). Epstein-Barr virus (EBV) infection has been ob-
served in 74% of published PBL cases (Castillo et al. 2008)
and may be involved in the pathogenesis of PBL (Raviele
et al. 2009). The role of Human Herpes Virus 8 (HHV8)
in the pathogenesis of PBL is uncertain (Castillo et al.
2008; Vega et al. 2005). Overall, prognosis in PBL of dis-
mal, with typically median survival of less than one year,
particularly in patients with extra-nodal disease (Thakral
et al. 2009; Teruya-Feldstein et al. 2004; Raviele et al.
2009). The advent of highly active antiretroviral therapy
(ART) has favorably impacted survival in HIV-positive pa-
tients in some studies (Teruya-Feldstein et al. 2004;
Valenzuela et al. 2008; Raviele et al. 2009). Contrarily,
other studies report poor progression-free survival and
overall survival despite intensive chemotherapeutic regi-
mens and ART (Castillo et al. 2012). Recently, it has
been suggested that HIV-negative patients with PBL
have a worse prognosis and a reduced response to
chemotherapy than their HIV-positive counterparts
on highly active antiretroviral therapy (Colomo et al.
2004; Liu et al. 2011). Nevertheless, the highly aggressive
and metastatic nature of PBL along with poor treatment
response renders long term survival disappointing
(Valenzuela et al. 2008).
Plasmablastic lymphoma is characterized by a terminally
differentiated B-cell immunophenotype with minimal or
absent expression of leukocyte common antigen (CD45),
epithelial markers and B-cell antigens (CD20 and CD79a)
but is invariably immunoreactive for well-differentiated
plasma cell markers such as CD138 and frequently
exhibits monotypic light chain expression (Thakral et al.
2009; Teruya-Feldstein et al. 2004; Raviele et al. 2009). PBL
shares many cytomorphologic and immunophenotypic fea-
tures with plasmablastic plasma cell myeloma (Vega et al.
2005). EBER positivity favors the diagnosis of PBL
(Vega et al. 2005; Ramalingam et al. 2008). CD56
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ever, its expression has been reported in PBL (Vega et al.
2005). Histopathologically, PBL shows a diffuse pattern
with a high mitotic index (Colomo et al. 2004; Scheper
et al. 2005).
Unified treatment guidelines for plasmablastic lymph-
oma have not been established and treatment regimes
have been largely varied and based upon physician discre-
tion. To date, the mainstay of treatment consists primarily
of chemotherapy, with the occasional use radiotherapy.
The present case is exceptional in that there are only a
few other instances in the literature (Kim et al. 2009;
Liu et al. 2011) where an HIV-negative, immunocompe-
tent patient with PBL has survived to the 4 year mark.
Treatment regimes for immunocompetent patients are
particularly sparse in the literature. CHOP and CVAD-
based therapies are the most widely used regimens (Liu
et al. 2011). Current clinical cases, treatment regimens
and outcomes are reported in Table 1.
CNS surveillance should be routinely employed in the
management of patients with PBL, particularly as disease
progression is widespread and typically involves the CNS
(Cha et al. 2010; Ramalingam et al. 2008). Our patient
was treated with 6 cycles of hyper-CVAD, CNS chemo-
prophylaxis and radiation therapy, with excellent results.
Nguyen et al. describe a patient with nasal cavity PBL
treated with three monthly courses of hyper-CVAD
chemotherapy with CNS prophylaxis [Table 1) using
intrathecal methotrexate with each cycle and consolidative
locoregional radiation therapy. Biopsy-confirmed (maxil-
lary sinus) complete remission (Nguyen et al. 2003) was
achieved.
As presently, for advanced PBL there is no definitive
treatment regimen capable of providing curative results.
Autologous or allogeneic stem cell transplantation is a
therapeutic option for relapsed or refractory disease.
Philip and colleagues (Philip et al. 1995) have shown that
high dose chemotherapy and autologous bone marrow
transplant may significantly improve overall survival in
patients with relapses following failed multi-agent
chemotherapy in non-Hodgkin’s lymphoma. Recently,
Liu et al. (Liu et al. 2011) reported success utilizing
consolidation with hematopoietic stem cell transplant in
patients with PBL who attained a first complete
remission.
Currently, specific randomized clinical trials supporting
stem cell transplantation for PBL are lacking. This fact,
coupled with the risk of significant transplantation-
related morbidity and mortality, suggests that the trans-
plant approach should be reserved for carefully selected
cases of PBL. Until a standardized chemotherapeutic
regime is identified, therapy for patients with PBL
should be considered on a case-by-case basis (Scheper
et al. 2005).Consent
Written informed consent was obtained from the patient
for publication of this report and any accompanying
images.
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